# Neoadjuvant Adebrelimab and Chemotherapy in High-rish ER+/HER2- BC

> **NCT06500208** · PHASE2 · RECRUITING · sponsor: **Shanghai Jiao Tong University School of Medicine** · enrollment: 48 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Adebrelimab combined with nab-paclitaxel, epirubicin and cyclophosphamide

## Key facts

- **NCT ID:** NCT06500208
- **Lead sponsor:** Shanghai Jiao Tong University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-01
- **Primary completion:** 2025-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2025-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06500208

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06500208, "Neoadjuvant Adebrelimab and Chemotherapy in High-rish ER+/HER2- BC". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT06500208. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*